{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:12:37Z","timestamp":1793646757851,"version":"4.5.1"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.jsat.2021.108394","type":"journal-article","created":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T20:48:49Z","timestamp":1617914929000},"page":"108394","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["The impact of COVID-19 on opioid treatment program (OTP) services: Where do we go from here?"],"prefix":"10.1016","volume":"131","author":[{"given":"Kathlene","family":"Tracy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Wachtel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teri","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsat.2021.108394_bb0005","series-title":"An epidemic in the midst of a pandemic: Opioid use disorder and COVID-19","author":"Alexander","year":"2020"},{"key":"10.1016\/j.jsat.2021.108394_bb0010","author":"Atterman"},{"issue":"87","key":"10.1016\/j.jsat.2021.108394_bb0015","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.biopsych.2019.06.020","article-title":"Medication treatment of opioid use disorder","volume":"1","author":"Bell","year":"2020","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.jsat.2021.108394_bb0020","author":"Centers for Disease Control and Prevention"},{"key":"10.1016\/j.jsat.2021.108394_bb0025","author":"Clay"},{"key":"10.1016\/j.jsat.2021.108394_bb0030","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/HRP.0000000000000075","article-title":"Medication-assisted treatment of opioid use disorder: Review of the evidence and future directions","author":"Connery","year":"2015","journal-title":"Harvard Review of Psychiatry"},{"key":"10.1016\/j.jsat.2021.108394_bb0035","author":"Hargan"},{"key":"10.1016\/j.jsat.2021.108394_bb0040","first-page":"1","article-title":"Rapid implementation of service delivery changes to mitigate COVID-19 and maintain access to methadone among persons with and at high-risk for HIV in an opioid treatment program","author":"Peavey","year":"2020","journal-title":"AIDS and Behavior."},{"key":"10.1016\/j.jsat.2021.108394_bb0045","author":"Substance Abuse and Mental Health Service Administration (SAMHSA)"},{"key":"10.1016\/j.jsat.2021.108394_bb0050","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/ajad.13031","article-title":"Editorial: Challenges to opioid use disorder during COVID-19","volume":"29","author":"Sun","year":"2020","journal-title":"The American Journal on Addictions"},{"key":"10.1016\/j.jsat.2021.108394_bb0055","author":"The Joint Commission"},{"key":"10.1016\/j.jsat.2021.108394_bb0060","series-title":"Collision of the COVID-19 and addiction epidemics","author":"Volkow","year":"2020"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547221001203?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547221001203?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:54:41Z","timestamp":1760039681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547221001203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":12,"alternative-id":["S0740547221001203"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2021.108394","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of COVID-19 on opioid treatment program (OTP) services: Where do we go from here?","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2021.108394","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108394"}}